Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wogonoside is a naturally occurring flavonoid glycoside, specifically the 7-O-glucuronide of wogonin, primarily found in traditional Chinese medicinal plants such as Scutellaria baicalensis. It exhibits potent **antitumor**, **anti-inflammatory**, **anticoagulant**, **anti-angiogenic**, and **antioxidant** activities. Mechanistically, wogonoside induces apoptosis via mitochondrial pathways (upregulation of Bax, downregulation of Bcl-2, activation of caspase-3/9), triggers endoplasmic reticulum (ER) stress-mediated cell death via activation of the IRE1α-TRAF2-ASK1 complex and the JNK pathway, and suppresses PI3K/Akt/mTOR/p70S6K signaling. It strongly inhibits angiogenesis by blocking vascular endothelial growth factor (VEGF) expression and Hedgehog signaling through Smoothened degradation, and may reduce inflammation by dual inhibition of NF-κB and the NLRP3 inflammasome. Wogonoside is being investigated as a lead compound for cancer therapy, especially in gastric, colon, and triple-negative breast cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wogonoside.